Clinical Science (2018) 132(4), 489–507;

The published article contains several errors introduced during the production process.

  1. In the penultimate sentence of the Introduction, the web address, incorrectly linked to a reference. The correct sentence is presented here:

    Furthermore, linagliptin is the first and so far only DPP-4 inhibitor to be evaluated in a randomized clinical trial designed to robustly assess renal outcomes: the ongoing Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA®; NCT01897532).

  2. In the captions to Figures 1 and 3, the reference citations attributed to statements of permission to reproduce were incorrect; the correct sources of the figures are presented here.

  • Figure 1 was reproduced from reference [18]: Shi, S., Koya, D. and Kanasaki, K. (2016) Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair 9, 1,

  • Figure 3 was reproduced from reference [107]: Zeisberg, M. and Zeisberg, E.M. (2015) Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int. 88, 429–431,

    Corrected online 8 January 2019.

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).